Literature DB >> 10791690

Gastric mucosal lesions induced by complete dopamine system failure in rats. The effects of dopamine agents, ranitidine, atropine, omeprazole and pentadecapeptide BPC 157.

P Sikiric1, J Separovic, G Buljat, T Anic, D Stancic-Rokotov, D Mikus, B Duplancic, A Marovic, I Zoricic, I Prkacin, M Lovric-Bencic, G Aralica, T Ziger, D Perovic, N Jelovac, G Dodig, I Rotkvic, S Mise, S Seiwerth, B Turkovic, Z Grabarevic, M Petek, R Rucman.   

Abstract

Up to now, for gastric lesions potentiation or induction, as well as determination of endogenous dopamine significance, dopamine antagonist or dopamine vesicle depletor were given separately. Therefore, without combination studies, the evidence for dopamine significance remains split on either blockade of dopamine post-synaptic receptor or inhibition of dopamine storage, essentially contrasting with endogenous circumstances, where both functions could be simultaneously disturbed. For this purpose, a co-administration of reserpine and haloperidol, a dopamine granule depletor combined with a dopamine antagonist with pronounced ulcerogenic effect, was tested, and the rats were sacrificed 24 h after injurious agent(s) administration. Haloperidol (5 mg x kg(-1) b.w. i.p.), given alone, produced the lesions in all rats. Reserpine (5 mg x kg(-1) b.w. i.p.), given separately, also produced lesions. When these agents were given together, the lesions were apparently larger than in the groups injured with separate administration of either haloperidol or reserpine alone. Along with our previous results, when beneficial agents were co-administered, all dopaminomimetics (bromocriptine 10 mg, apomophine 1 mg, amphetamine 20 mg x kg(-1) i.p.) apparently attenuated the otherwise consistent haloperidol-gastric lesions. Likewise, an apparent inhibition of the reserpine-lesions was noted as well. However, if they were given in rats injured with combination of haloperidol and reserpine, their otherwise prominent beneficial effects were absent. Ranitidine (10 mg), omeprazole (10 mg), atropine (10 mg), pentadecapeptide BPC 157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) (10 microg or 10 ng x kg(-1) i.p.) evidently prevented both haloperidol-gastric lesions and reserpine-gastric lesions. Confronted with potentiated lesions following a combination of haloperidol and reserpine, these agents maintained their beneficial effects, noted in the rats treated with either haloperidol or reserpine alone. The failure of dopaminomimetics could be most likely due to more extensive inhibition of endogenous dopamine system activity, and need for remained endogenous dopamine for their salutary effect, whereas the beneficial activities of ranitidine, omeprazole, atropine, pentadecapeptide BPC 157 following dopamine system inhibition by haloperidol+reserpine suggest their corresponding systems parallel those of dopamine system, and they may function despite extensive inhibition of endogenous dopamine system activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10791690     DOI: 10.1016/s0928-4257(00)00147-9

Source DB:  PubMed          Journal:  J Physiol Paris        ISSN: 0928-4257


  6 in total

1.  Protective effects of amphetamine on gastric ulcerations induced by indomethacin in rats.

Authors:  Vlaicu Sandor; Barbu Cuparencu; Dan-L Dumitrascu; Mircea-A Birt; Tibor-L Krausz
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

2.  Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, L-NAME, pentadecapeptide BPC 157 and L-arginine.

Authors:  Zeljka Belosic Halle; Josipa Vlainic; Domagoj Drmic; Dean Strinic; Kresimir Luetic; Mario Sucic; Maria Medvidovic-Grubisic; Tatjana Pavelic Turudic; Igor Petrovic; Sven Seiwerth; Predrag Sikiric
Journal:  Inflammopharmacology       Date:  2017-05-17       Impact factor: 4.473

3.  Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats.

Authors:  Xiao-Chang Xue; Yong-Jie Wu; Ming-Tang Gao; Wen-Guang Li; Ning Zhao; Zeng-Lu Wang; Chun-Jie Bao; Zhen Yan; Ying-Qi Zhang
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

4.  Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.

Authors:  Tonglie Huang; Kuo Zhang; Lijuan Sun; Xiaochang Xue; Cun Zhang; Zhen Shu; Nan Mu; Jintao Gu; Wangqian Zhang; Yukun Wang; Yingqi Zhang; Wei Zhang
Journal:  Drug Des Devel Ther       Date:  2015-04-30       Impact factor: 4.162

Review 5.  Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future.

Authors:  Predrag Sikiric; Ki-Baik Hahm; Alenka Boban Blagaic; Ante Tvrdeic; Katarina Horvat Pavlov; Andrea Petrovic; Antonio Kokot; Slaven Gojkovic; Ivan Krezic; Domagoj Drmic; Rudolf Rucman; Sven Seiwerth
Journal:  Gut Liver       Date:  2020-03-15       Impact factor: 4.519

Review 6.  Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.

Authors:  Predrag Sikiric; Sven Seiwerth; Rudolf Rucman; Danijela Kolenc; Lovorka Batelja Vuletic; Domagoj Drmic; Tihomir Grgic; Sanja Strbe; Goran Zukanovic; Dalibor Crvenkovic; Goran Madzarac; Iva Rukavina; Mario Sucic; Marko Baric; Neven Starcevic; Zoran Krstonijevic; Martina Lovric Bencic; Igor Filipcic; Dinko Stancic Rokotov; Josipa Vlainic
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.